S‑1‑containing chemotherapy for patients with non‑small‑cell lung cancer: A population‑based observational study by the Ibaraki thoracic integrative (POSITIVE) research group

Inagaki,Masaharu; Shinohara,Yoko; Kaburagi,Takayuki; Endo,Takeo; Homma,Shinsuke; Hizawa,Nobuyuki; Kishi,Koji; Nakamura,Hiroyuki; Hayashihara,Kenji; Saito,Takefumi; Kurishima,Koichi; Ishikawa,Hiroichi; Ichimura,Hideo; Nawa,Takeshi; Kikuchi,Norihiro; Miyazaki,Kunihiko; Kodama,Takahide; Satoh,Hiroaki; Furukawa,Kinya

doi:10.3892/mco.2016.826

S‑1‑containing chemotherapy for patients with non‑small‑cell lung cancer: A population‑based observational study by the Ibaraki thoracic integrative (POSITIVE) research group

Authors:
- Masaharu Inagaki
- Yoko Shinohara
- Takayuki Kaburagi
- Takeo Endo
- Shinsuke Homma
- Nobuyuki Hizawa
- Koji Kishi
- Hiroyuki Nakamura
- Kenji Hayashihara
- Takefumi Saito
- Koichi Kurishima
- Hiroichi Ishikawa
- Hideo Ichimura
- Takeshi Nawa
- Norihiro Kikuchi
- Kunihiko Miyazaki
- Takahide Kodama
- Hiroaki Satoh
- Kinya Furukawa
View Affiliations

Affiliations: Tsuchiura Kyodo General Hospital and Regional Cancer Center, Tsuchiura, Ibaraki 300‑0053, Japan, Ibaraki Prefectural Central Hospital and Regional Cancer Center, Kasama, Ibaraki 309‑1793, Japan, Mito Medical Center Hospital, Mito, Ibaraki 311‑3193, Japan, Faculty of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki 305‑8576, Japan, Tokyo Medical University, Ibaraki Medical Center Hospital, Ami, Ibaraki 300‑0395, Japan, Ibaraki Higashi National Hospital, Tokai, Ibaraki 319‑1113, Japan, Tsukuba Medical Center Hospital and Regional Cancer Center, Tsukuba, Ibaraki 305‑8558, Japan, Hitachi General Hospital, Hitachi, Ibaraki 317‑0077, Japan, Kasumigaura Medical Center, Tsuchiura, Ibaraki 300‑0812, Japan, Ryugasaki Saiseikai General Hospital, Ryugasaki, Ibaraki 301‑0854, Japan, Division of Respiratory Medicine, Μito Medical Center, Institute of Clinical Medicine, University of Tsukuba, Mito, Ibaraki 310‑0015, Japan
Published online on: March 21, 2016 https://doi.org/10.3892/mco.2016.826
Pages: 1025-1030

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To evaluate the efficacy and safety of S‑1 monotherapy, S‑1‑containing combined chemotherapy and S‑1 containing chemoradiotherapy for non‑small cell lung cancer (NSCLC), a population‑based observational study was performed. The efficacy and safety of the chemotherapies were evaluated at 13 institutes in a prefecture of Japan between April 2011 and March 2015. Datasets were obtained from 282 patients with NSCLC. For either wild‑type or mutated epidermal growth factor receptor (EGFR), these three therapy groups generated almost identical response results and toxicity profiles as those in previously reported clinical trials, although the present study appeared to have slightly lower survival rates compared with those in the previous clinical trials. This may be due to the inclusion of patients in poor condition, and S‑1 therapy being administered in the second, or later, line of therapy. In conclusion, the present study has confirmed that S‑1‑containing chemotherapy is effective against wild‑ and mutated‑type EGFR NSCLC, and it is also tolerable in clinical practice.

View Figures

View References

1	Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 7:548–557. 1996. View Article : Google Scholar : PubMed/NCBI
2	Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, Hasegawa K and Niitani H: S-1 Cooperative Study Group (Lung Cancer Working Group): Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer. 85:939–943. 2001. View Article : Google Scholar : PubMed/NCBI
3	Shiroyama T, Kijima T, Komuta K, Yamamoto S, Minami S, Ogata Y, Okafuji K, Imamura F, Hirashima T, Tachibana I, et al: Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer. Cancer Chemother Pharmacol. 70:783–789. 2012. View Article : Google Scholar : PubMed/NCBI
4	Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Asami K, Hirashima T, et al: Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: Results of a west Japan oncology group study. J Clin Oncol. 28:5240–5246. 2010. View Article : Google Scholar : PubMed/NCBI
5	Ono A, Naito T, Murakami H, Takahashi T, Nakamura Y, Tsuya A, Kaira K, Igawa S, Shukuya T, Tamiya A, et al: Evaluation of S-1 as third or further-line chemotherapy in advanced non-small-cell lung cancer. Int J Clin Oncol. 15:161–165. 2010. View Article : Google Scholar : PubMed/NCBI
6	Ohyanagi F, Yamamoto N, Horiike A, Harada H, Kozuka T, Murakami H, Gomi K, Takahashi T, Morota M, Nishimura T, et al: Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Br J Cancer. 101:225–231. 2009. View Article : Google Scholar : PubMed/NCBI
7	Richardson GE, Thursfield VJ and Giles GG: Reported management of lung cancer in Victoria in 1993: Comparison with best practice. Anti-cancer council of victoria lung cancer study group. Med J Aust. 172:321–324. 2000.PubMed/NCBI
8	Sambrook RJ and Girling DJ: A national survey of the chemotherapy regimens used to treat small cell lung cancer (SCLC) in the United Kingdom. Br J Cancer. 84:1447–1452. 2001. View Article : Google Scholar : PubMed/NCBI
9	Gregor A, Thomson CS, Brewster DH, Stroner PL, Davidson J, Fergusson RJ and Milroy R: Scottish Cancer Trials Lung Group; Scottish Cancer Therapy Network: Management and survival of patients with lung cancer in Scotland diagnosed in 1995: Results of a national population based study. Thorax. 56:212–217. 2001. View Article : Google Scholar : PubMed/NCBI
10	Lebitasy MP, Hédelin G, Purohit A, Moreau L, Klinzig F and Quoix E: Progress in the management and outcome of small-cell lung cancer in a French region from 1981 to 1994. Br J Cancer. 85:808–815. 2001. View Article : Google Scholar : PubMed/NCBI
11	Chang GC, Chen KC, Yang TY, Yin MC, Lin CP, Kuo BI and Hsu JY: Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status. Invest New Drugs. 23:73–77. 2005. View Article : Google Scholar : PubMed/NCBI
12	Hayashibara K, Satoh H, Shinohara Y, Inagaki M, Kaburagi T, Hashimoto T, Kurishima K, Ishikawa H, Ichimura H, Nawa T, et al: A population-based study of gefitinib in patients with non-small cell lung cancer. Med Oncol. 26:222–227. 2009. View Article : Google Scholar : PubMed/NCBI
13	Nakamura H, Satoh H, Kaburagi T, Nishimura Y, Shinohara Y, Inagaki M, Endo T, Saito T, Hayashihara K, Hizawa N, et al: Bevacizumab-containing chemotherapy for non-small cell lung cancer patients: A population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group. Med Oncol. 29:3202–3206. 2012. View Article : Google Scholar : PubMed/NCBI
14	Kaburagi T, Satoh H, Hayashihara K, Endo T, Hizawa N, Kurishima K, Nishimura Y, Hashimoto T, Nakamura H, Kishi K, et al: Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer. Oncol Lett. 5:435–439. 2013.PubMed/NCBI
15	Cancer Therapy Evaluation Program, Common Toxicity Criteria for Adverse Events. Version 3.0, CTCAE Version 3.0. June 10–2003.http://ctep.cancer.govAccessed. May 15–2014
16	Reck M, Heigener DF, Mok T, Soria JC and Rabe KF: Management of non-small-cell lung cancer: Recent developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
17	Chen YM: Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer. J Chin Med Assoc. 76:249–257. 2013. View Article : Google Scholar : PubMed/NCBI
18	Totani Y, Saito Y, Hayashi M, Tada T, Kohashi Y, Mieno Y, Kato A, Imizu H, Yoneda Y, Hoshino T, et al: A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 64:1181–1185. 2009. View Article : Google Scholar : PubMed/NCBI
19	Katakami N, Gemma A, Sakai H, Kubota K, Nishio M, Inoue A, Okamoto H, Isobe H, Kunitoh H, Takiguchi Y, et al: Randomized phase III trial of S-1 plus cisplatin versus docetaxel plus cisplatin for advanced non-small-cell lung cancer (TCOG0701). J Clin Oncol. 30(Suppl): abstract 75152012.
20	Yoshioka H, Okamoto I, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Atagi S, Hirashima T, et al: Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: Updated results of the West Japan Oncology Group LETS study. Ann Oncol. 24:1326–1331. 2013. View Article : Google Scholar : PubMed/NCBI
21	Ichinose Y, Seto T, Sasaki T, Yamanaka T, Okamoto I, Takeda K, Tanaka M, Katakami N, Sawa T, Kudoh S, et al: S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: A multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706). J Thoracic Oncol. 6:2069–2075. 2011. View Article : Google Scholar